DTIL

Announcements

Nothing here yet

Daily updates

• All patient cohorts completed dosing in Phase 1/2 OTC-HOPE trial of ECUR-506Aug 27, 2026

FDA designations

• Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyJul 23, 2025

News

• Precision BioSciences began dosing patients in the Phase 1/2 FUNCTION-DMD studyAug 24, 2026
• iECURE announced plans to present clinical data from the ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiencyAug 20, 2026
• iECURE reported sustained clinical response and reduced hyperammonemic events in the OTC-HOPE trial of ECUR-506May 18, 2026
• Precision BioSciences activated the first clinical trial site and started patient enrollment in the Phase 1/2 FUNCTION-DMD studyApr 29, 2026
• Precision BioSciences received U.S. patent allowances covering the PBGENE-HBV programMar 11, 2026